Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI)
have profoundly changed the natural history of the disease with a major impact on survival …

During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the
natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and …

Chronic myeloid leukemia (CML) is a classical example of stem cell cancer since it arises in
a multipotent hematopoietic stem cell upon the acquisition of the t (9; 22) chromosomal …

Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized
by the translocation t (9; 22), coding for the chimeric protein BCR-ABL. The development of …

In patients with chronic myeloid leukemia (CML) in chronic phase who have achieved
complete molecular remission on imatinib therapy, clinical trials from France and Australia …

The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has
proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival …

Nowadays, more than 90% of patients affected by chronic myeloid leukemia (CML) survive
with a good quality of life, thanks to the clinical efficacy of tyrosine kinase inhibitors (TKIs) …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the
acquired chromosomal translocation BCR-ABL. This gives rise to a constitutively active …

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …